FOSAMAX
What it isBone-binding FPPS inhibitor that suppresses osteoclasts; first-line oral treatment for osteoporosis.
Why this oneHip and vertebral fracture evidence, generic cost and a weekly tablet make it the benchmark oral bisphosphonate.
What limits itTake fasting with water and stay upright to prevent esophagitis. Avoid severe renal impairment; long use rarely injures the jaw or femur.
Read the full label on DailyMed ↗
| FDA dosing | Population | Start | Target | Max |
|---|---|---|---|---|
| Osteoporosis treatment (postmenopausal women) | 10 mg QD or 70 mg once weekly | |||
| Osteoporosis prevention (postmenopausal women) | 5 mg QD or 35 mg once weekly | |||
| Increase bone mass in men | 10 mg QD or 70 mg once weekly | |||
| Glucocorticoid-induced osteoporosis | 5 mg QD (10 mg QD if postmenopausal, not on estrogen) | |||
| Paget's disease of bone | 40 mg QD for 6 months |
Renal Not recommended if CrCl <35 mL/min; no adjustment for CrCl 35-60 mL/min
Hepatic No dosage adjustment necessary
Pregnancy Insufficient data; discontinue when pregnancy is recognized. Bisphosphonates incorporate into bone with potential for fetal skeletal harm.
Lactation Not known whether alendronate is present in human milk or affects the breastfed infant.
NO BOXED WARNINGS
Principal riskEsophagitis; remain upright for 30 minutes
Cost, est. cash$4–$80/month
Generic entry2008
Legacy pregnancy categoryC
Defining liabilityEsophageal injury and rare osteonecrosis/atypical fracture; administration technique matters.

Open Alendronate in the interactive console ↗

